Personal information

Emails & domains

Verified email addresses

Websites & social links

Researchgate profile

Other IDs

Scopus Author ID: 56619801800

Keywords

neurology, epilepsy, tuberous sclerosis

Countries

Poland

Activities

Collapse all

Employment (1)

Children's Memorial Health Institute: Warsaw, PL

2015-01-02 to present | MD PhD (Neurology and Epileptology Department)
Employment
Source: Self-asserted source
Krzysztof Sadowski

Works (9)

Early diagnosis of tuberous sclerosis complex: A race against time. How to make the diagnosis before seizures?

Orphanet Journal of Rare Diseases
2018 | Journal article
DOI: 10.1186/s13023-018-0764-z
EID:

2-s2.0-85041196459
Contributors: Słowińska, M.; Jóźwiak, S.; Peron, A.; Borkowska, J.; Chmielewski, D.; Sadowski, K.; Jurkiewicz, E.; Vignoli, A.; La Briola, F.; Canevini, M.P. et al.
Source: Self-asserted source
Krzysztof Sadowski via Scopus - Elsevier

Liver Angiomyolipomas in Tuberous Sclerosis Complex—Their Incidence and Course

Pediatric Neurology
2018 | Journal article
DOI: 10.1016/j.pediatrneurol.2017.09.012
EID:

2-s2.0-85039413530
Contributors: Jóźwiak, S.; Sadowski, K.; Borkowska, J.; Domańska-Pakieła, D.; Chmielewski, D.; Jurkiewicz, E.; Jaworski, M.; Urbańska, M.; Ogrodnik, M.; Słowińska, M. et al.
Source: Self-asserted source
Krzysztof Sadowski via Scopus - Elsevier

Topical Use of Mammalian Target of Rapamycin (mTOR) Inhibitors in Tuberous Sclerosis Complex-A Comprehensive Review of the Literature.

2016-08 | Journal article
DOI: 10.1016/j.pediatrneurol.2016.04.003
PMID: 27222056
Contributors: Jóźwiak S; Sadowski K; Kotulska K; Schwartz RA
Source: Self-asserted source
Krzysztof Sadowski via Europe PubMed Central
grade
Preferred source (of 2)‎

Management of side effects of mTOR inhibitors in tuberous sclerosis patients.

2016-06 | Journal article
DOI: 10.1016/j.pharep.2016.01.005
PMID: 26891243
Contributors: Sadowski K; Kotulska K; Jóźwiak S
Source: Self-asserted source
Krzysztof Sadowski via Europe PubMed Central
grade
Preferred source (of 2)‎

Systemic effects of treatment with mTOR inhibitors in tuberous sclerosis complex: a comprehensive review.

2016-04 | Journal article
DOI: 10.1111/jdv.13356
PMID: 26403211
Contributors: Sadowski K; Kotulska K; Schwartz RA; Jóźwiak S
Source: Self-asserted source
Krzysztof Sadowski via Europe PubMed Central
grade
Preferred source (of 2)‎

Basal ganglia echogenicity in tauopathies.

2015-06 | Journal article
DOI: 10.1007/s00702-014-1310-3
PMID: 25204278
PMC: PMC4449374
Contributors: Sadowski K; Serafin-Król M; Szlachta K; Friedman A
Source: Self-asserted source
Krzysztof Sadowski via Europe PubMed Central
grade
Preferred source (of 2)‎

Role of mTOR inhibitors in epilepsy treatment.

2015-06 | Journal article
DOI: 10.1016/j.pharep.2014.12.017
PMID: 25933981
Contributors: Sadowski K; Kotulska-Jóźwiak K; Jóźwiak S
Source: Self-asserted source
Krzysztof Sadowski via Europe PubMed Central
grade
Preferred source (of 2)‎

Different signals of magnetic resonance imaging and ultrasound from substantia nigra in Parkinson's disease and control - Is iron the cause?

Acta Physica Polonica A
2012 | Journal article
DOI: 10.12693/APhysPolA.121.454
EID:

2-s2.0-84857385708
Contributors: Szlachta, K.; Sadowski, K.; Kuliński, R.; Gała̧zka-Friedman, J.; Friedman, A.
Source: Self-asserted source
Krzysztof Sadowski via Scopus - Elsevier

Brain tissue echogenicity--implications for substantia nigra studies in parkinsonian patients.

2012-03 | Journal article
DOI: 10.1007/s00702-011-0707-5
PMID: 21881837
PMC: PMC3282899
Contributors: Sadowski K; Szlachta K; Serafin-Król M; Gałązka-Friedman J; Friedman A
Source: Self-asserted source
Krzysztof Sadowski via Europe PubMed Central
grade
Preferred source (of 2)‎
How many people are using ORCID?